Advances in the Treatment of Metastatic Renal Cell Carcinoma
The treatment landscape for metastatic renal cell carcinoma has constantly been in flux. In 2005, with the advent of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy, the standard of care shifted to agents such as sunitinib and pazopanib. However, more recently there have been datasets, suggesting that next-generation TKIs such as cabozantinib may play an important role in therapy. Furthermore, immunotherapy has had resurgence with the FDA approval of nivolumab with ipilimumab. In the current chapter, we attempt to contextualize available frontline therapies for metastatic renal cell carcinoma with a focus on the CABOSUN and CheckMate 214 clinical trials.
KeywordsCheckMate 214 CABOSUN Metastatic
Conflict of Interest SKP declares consulting agreements with Genentech, Roche, Exelixis, BMS, Ipsen, Novartis, Astellas, Eisai and Pfizer.
- 9.Atzpodien J, Kirchner H, Jonas U et al (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol: Official J Am Soc Clin Oncol 22:1188–1194CrossRefGoogle Scholar
- 16.Cancer Genome Atlas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43–49 Google Scholar
- 18.Hammers HJ, Plimack ER, Sternberg C, et al (2015) CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 33:TPS4578–TPSGoogle Scholar
- 19.Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol: Official J Am Soc Clin Oncol 27:5794–5799CrossRefGoogle Scholar
- 20.Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Plimack ER, Barthelemy P, George S, Neiman V, Porta C, Choueiri TK, Powles T, Donskov F, Salman P, Kollmannsberger CK, Rini B, Mekan S, McHenry MB, Wind‐Rotolo M, Hammers HJ, Escudier B (2017) Nivolumab + Ipilimumab (N + I) versus Sunitinib (S) for treatment‐naïve advanced or metastatic renal cell carcinoma (aRCC): results from CheckMate 214, including overall survival by subgroups. SITC 2017 ANNUAL MEETING ABSTRACTS BOOK. Maryland: Society for Immunotherapy of Cancer p 103Google Scholar
- 24.NIH U.S. National library of medicine https://clinicaltrials.gov/ Accessed January 10, 2018
- 27.Lee CVM, Rasco D, Taylor M, Dutcus C, Shumaker R., Schmidt EV, Stepan D., Li D, Motzer RJ (2017) Anti-Cancer Agents & Biologic Therapy Renal Cell Cancer Cancer Immunology and Immunotherapy Genitourinary Cancers. ESMO 2017 Congress. Madrid, Spain: Annals of Oncology v295–v329. 10.1093Google Scholar
- 28.Hahn AW, Gill DM, Maughan B et al (2017) Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget 8:33614–33620PubMedPubMedCentralGoogle Scholar
- 29.Becerra MF, Reznik E, Redzematovic A, et al (2017) Comparative genomic profiling of matched primary and metastatic tumors in renal cell carcinoma. Eur Urol FocusGoogle Scholar